Windtree Therapeutics Files S-1/A Amendment

Ticker: WINTW · Form: S-1/A · Filed: Apr 23, 2025 · CIK: 946486

Windtree Therapeutics Inc /De/ S-1/A Filing Summary
FieldDetail
CompanyWindtree Therapeutics Inc /De/ (WINTW)
Form TypeS-1/A
Filed DateApr 23, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, registration, biotech

TL;DR

WINT files S-1/A, looks like they're raising cash.

AI Summary

Windtree Therapeutics, Inc. filed an S-1/A amendment on April 23, 2025, for its registration statement. The company, formerly known as Discovery Laboratories Inc., is incorporated in Delaware and headquartered in Warrington, Pennsylvania. This filing relates to the registration of securities under the Securities Act of 1933.

Why It Matters

This S-1/A filing indicates Windtree Therapeutics is moving forward with a securities offering, which could provide capital for its operations and drug development pipeline.

Risk Assessment

Risk Level: medium — As a biotechnology company, Windtree Therapeutics is subject to inherent risks associated with drug development, regulatory approvals, and market acceptance.

Key Numbers

  • 20250423 — Filing Date (Date of the S-1/A amendment filing.)
  • 19971201 — Name Change Date (Date Windtree Therapeutics changed its name from Discovery Laboratories Inc.)

Key Players & Entities

  • WINDTREE THERAPEUTICS INC (company) — Registrant
  • Discovery Laboratories Inc (company) — Former company name
  • 2600 Kelly Road, Suite 100 Warrington, Pennsylvania 18976 (address) — Principal executive offices
  • Jed Latkin (person) — President and Chief Executive Officer
  • 333-284976 (registration_number) — SEC File Number

FAQ

What is the purpose of this S-1/A filing?

This S-1/A filing is an amendment to a registration statement under the Securities Act of 1933, indicating Windtree Therapeutics is updating information related to a securities offering.

When was Windtree Therapeutics previously known by another name?

Windtree Therapeutics was formerly known as Discovery Laboratories Inc., with a name change date of December 1, 1997.

Where is Windtree Therapeutics' principal executive office located?

The company's principal executive offices are located at 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.

Who is the President and Chief Executive Officer of Windtree Therapeutics?

Jed Latkin serves as the President and Chief Executive Officer of Windtree Therapeutics.

What is the SEC file number for this registration statement?

The SEC file number for this registration statement is 333-284976.

Filing Details

This Form S-1/A (Form S-1/A) was filed with the SEC on April 23, 2025 by Jed Latkin regarding WINDTREE THERAPEUTICS INC /DE/ (WINTW).

View full filing on EDGAR

View Full Filing

View this S-1/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.